enfortumab vedotin + pembrolizumab

Phase 2Recruiting

0 views this week 0 watching⚡ Active

Interest: 42/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Melanoma

Conditions

Melanoma

Trial Timeline

Jun 10, 2025 → Jun 1, 2028

NCT ID

NCT06906822

About enfortumab vedotin + pembrolizumab

enfortumab vedotin + pembrolizumab is a phase 2 stage product being developed by Astellas Pharma for Melanoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06906822. Target conditions include Melanoma.

What happened to similar drugs?

4 of 20 similar drugs in Melanoma were approved

Approved (4) Terminated (2) Active (14)

✅dabrafenib + trametinibNovartisApproved

✅ZelborafRocheApproved

✅Nivolumab + RelatlimabBristol Myers SquibbApproved

✅Fibrin Sealant (Tisseel) used in the Experimental Arm.BaxterApproved

❌Tasisulam-sodium + PaclitaxelEli LillyPhase 3

🔄Pembrolizumab + Lenvatinib + Placebo for lenvatinibEisaiPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07475806	Phase 2	Recruiting	Mar 31, 2026	Apr 30, 2031	Muscle-invasive Bladder Cancer
NCT06906822	Phase 2	Recruiting	Jun 10, 2025	Jun 1, 2028	Melanoma
NCT06809140	Phase 2	Recruiting	Apr 7, 2025	Nov 1, 2029	Muscle Invasive Bladder Urothelial Carcinoma
NCT06470282	Phase 1/2	Recruiting	Mar 31, 2025	Jan 31, 2028	Bladder Cancer
NCT05756569	Phase 2	Recruiting	Sep 26, 2023	Dec 16, 2027	Bladder Squamous Cell Carcinoma
NCT05239624	Phase 2	Recruiting	Jun 2, 2022	Jun 1, 2027	Urothelial Carcinoma
NCT04225117	Phase 2	Active	Mar 9, 2020	Sep 30, 2026	Locally Advanced or Metastatic Malignant Solid Tumors

Competing Products

20 competing products in Melanoma

See all competitors

Product	Company	Stage	Hype Score
mRNA-4157 + Pembrolizumab	Merck	Phase 2	39
AVT32-DRL_PB + Keytruda	Dr. Reddy's Laboratories	Phase 1	33
Binimetinib Oral Tablet	Biotrial	Phase 1	15
Tasisulam-sodium + Paclitaxel	Eli Lilly	Phase 3	32
[203Pb]VMT01 + [212Pb]VMT01 + Nivolumab	Perspective Therapeutics	Phase 1/2	33
[203Pb]VMT01 + [68Ga]VMT02	Perspective Therapeutics	Phase 1	23
FYB206 + Keytruda	Formycon AG	Phase 1	23
PLX3397	Daiichi Sankyo	Pre-clinical	26
PLX3397 + Pembrolizumab	Daiichi Sankyo	Phase 1/2	24
Trastuzumab deruxtecan	Daiichi Sankyo	Phase 2	39
DS-8273a + Nivolumab	Daiichi Sankyo	Phase 1	29
PLX3397 + vemurafenib	Daiichi Sankyo	Phase 1	21
CP-461	Astellas Pharma	Phase 2	27
YM155	Astellas Pharma	Phase 2	35
YM155 + Docetaxel	Astellas Pharma	Phase 2	35
Denileukin diftitox	Eisai	Phase 2	35
E7080	Eisai	Phase 1	29
lenvatinib + pembrolizumab	Eisai	Phase 2	35
MORAb-004 (monoclonal antibody)	Eisai	Phase 2	35
Pembrolizumab + Lenvatinib	Eisai	Phase 2	39